Your browser doesn't support javascript.
loading
Adoptive immunotherapy with autologous T-cell infusions reduces opioid requirements in advanced cancer patients.
Zhou, Xinna; Qiao, Guoliang; Ren, Jun; Wang, Xiaoli; Wang, Shuo; Zhu, Siyu; Yuan, Yanhua; Morse, Michael A; Hobeika, Amy; Lyerly, Herbert Kim.
Afiliación
  • Zhou X; Department of Medical Oncology, Beijing Key Laboratory for Therapeutic Cancer Vaccines, Capital Medical University Cancer Center, Beijing Shijitan Hospital, Capital Medical University, Beijing, China.
  • Qiao G; Department of Medical Oncology, Beijing Key Laboratory for Therapeutic Cancer Vaccines, Capital Medical University Cancer Center, Beijing Shijitan Hospital, Capital Medical University, Beijing, China.
  • Ren J; Department of Medical Oncology, Beijing Key Laboratory for Therapeutic Cancer Vaccines, Capital Medical University Cancer Center, Beijing Shijitan Hospital, Capital Medical University, Beijing, China.
  • Wang X; Department of Surgery, Duke University Medical Center, Durham, United States.
  • Wang S; Department of Medical Oncology, Beijing Key Laboratory for Therapeutic Cancer Vaccines, Capital Medical University Cancer Center, Beijing Shijitan Hospital, Capital Medical University, Beijing, China.
  • Zhu S; Department of Medical Oncology, Beijing Key Laboratory for Therapeutic Cancer Vaccines, Capital Medical University Cancer Center, Beijing Shijitan Hospital, Capital Medical University, Beijing, China.
  • Yuan Y; Department of Medical Oncology, Beijing Key Laboratory for Therapeutic Cancer Vaccines, Capital Medical University Cancer Center, Beijing Shijitan Hospital, Capital Medical University, Beijing, China.
  • Morse MA; Department of Medical Oncology, Beijing Key Laboratory for Therapeutic Cancer Vaccines, Capital Medical University Cancer Center, Beijing Shijitan Hospital, Capital Medical University, Beijing, China.
  • Hobeika A; Department of Surgery, Duke University Medical Center, Durham, United States.
  • Lyerly HK; Department of Medicine, Duke University Medical Center, Durham, United States.
Pain ; 161(1): 127-134, 2020 01.
Article en En | MEDLINE | ID: mdl-31568023
Asunto(s)
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Linfocitos T / Inmunoterapia Adoptiva / Manejo del Dolor / Dolor en Cáncer Tipo de estudio: Observational_studies / Prognostic_studies / Risk_factors_studies Límite: Adult / Aged / Female / Humans / Male / Middle aged Idioma: En Revista: Pain Año: 2020 Tipo del documento: Article País de afiliación: China
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Linfocitos T / Inmunoterapia Adoptiva / Manejo del Dolor / Dolor en Cáncer Tipo de estudio: Observational_studies / Prognostic_studies / Risk_factors_studies Límite: Adult / Aged / Female / Humans / Male / Middle aged Idioma: En Revista: Pain Año: 2020 Tipo del documento: Article País de afiliación: China